Cargando…

Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT

RATIONALE: There is an association between body mass index (BMI) and mortality in chronic obstructive pulmonary disease (COPD), with underweight individuals having higher mortality risk. Mortality and exacerbation risks among individuals with higher BMI are unclear. OBJECTIVES: To examine the relati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Putcha, Nirupama, Anzueto, Antonio R., Calverley, Peter M. A., Celli, Bartolomé R., Tashkin, Donald P., Metzdorf, Norbert, Mueller, Achim, Wise, Robert A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867355/ https://www.ncbi.nlm.nih.gov/pubmed/34406915 http://dx.doi.org/10.1513/AnnalsATS.202006-722OC

Ejemplares similares

Determinants of exacerbation risk in patients with COPD in the TIOSPIR study
por: Calverley, Peter MA, et al.
Publicado: (2017)

Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR(®) trial
por: Wise, Robert A, et al.
Publicado: (2018)

Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial
por: Tashkin, Donald P., et al.
Publicado: (2018)

The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes
por: Anzueto, Antonio, et al.
Publicado: (2015)

Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial
por: Dahl, Ronald, et al.
Publicado: (2015)

Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD
por: Calverley, Peter MA, et al.
Publicado: (2018)

Differences in outcomes between GOLD groups in patients with COPD in the TIOSPIR(®) trial
por: Dusser, Daniel, et al.
Publicado: (2016)

Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial
por: Wise, Robert, et al.
Publicado: (2015)

Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT® trial
por: Celli, Bartolomé R., et al.
Publicado: (2016)

Discordance in investigator-reported and adjudicated sudden death in TIOSPIR
por: Wise, Robert A., et al.
Publicado: (2017)

Risk of Nonlower Respiratory Serious Adverse Events Following COPD Exacerbations in the 4-year UPLIFT(®) Trial
por: Halpin, David M. G., et al.
Publicado: (2011)

Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial
por: Hanania, Nicola A, et al.
Publicado: (2011)

Adverse health consequences in COPD patients with rapid decline in FEV(1 )- evidence from the UPLIFT trial
por: Kesten, Steven, et al.
Publicado: (2011)

Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial
por: Tashkin, Donald P, et al.
Publicado: (2015)

Impact and prevention of severe exacerbations of COPD: a review of the evidence
por: Halpin, David MG, et al.
Publicado: (2017)

Exacerbation frequency and course of COPD
por: Halpin, David MG, et al.
Publicado: (2012)

The Tiotropium Safety and Performance in Respimat® Trial (TIOSPIR®), a large scale, randomized, controlled, parallel-group trial-design and rationale
por: Wise, Robert A, et al.
Publicado: (2013)

Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT(®) studies
por: Miravitlles, Marc, et al.
Publicado: (2009)

Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials
por: Cooper, Christopher B, et al.
Publicado: (2011)

Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study
por: Morjaria, Jaymin B., et al.
Publicado: (2017)

Factors associated with change in exacerbation frequency in COPD
por: Donaldson, Gavin C, et al.
Publicado: (2013)

Preventing and managing exacerbations in COPD – critical appraisal of the role of tiotropium
por: Tashkin, Donald P
Publicado: (2010)

A score to predict short-term risk of COPD exacerbations (SCOPEX)
por: Make, Barry J, et al.
Publicado: (2015)

The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials
por: Eriksson, Göran, et al.
Publicado: (2017)

Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial
por: Goossens, Lucas M A, et al.
Publicado: (2014)

Optimizing bronchodilation in the prevention of COPD exacerbations
por: Miravitlles, Marc, et al.
Publicado: (2017)

Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations
por: Calverley, Peter M, et al.
Publicado: (2016)

The BODECOST Index (BCI): a composite index for assessing the impact of COPD in real life
por: Dal Negro, Roberto W., et al.
Publicado: (2016)

Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD
por: Tashkin, Donald P, et al.
Publicado: (2014)

Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial
por: Watz, Henrik, et al.
Publicado: (2018)

Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD
por: Cazzola, Mario, et al.
Publicado: (2023)

Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial
por: Rabe, Klaus F., et al.
Publicado: (2020)

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis
por: Halpin, David MG, et al.
Publicado: (2015)

International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials
por: Calverley, Peter M. A., et al.
Publicado: (2022)

Tiotropium HandiHaler(®) in the treatment of COPD: A safety review
por: Kesten, Steven, et al.
Publicado: (2009)

The need to further understand who gets hospitalized for a COPD exacerbation
por: Maselli, Diego J, et al.
Publicado: (2012)

Effect of tiotropium on night-time awakening and daily rescue medication use in patients with COPD
por: Calverley, Peter M. A., et al.
Publicado: (2016)

Recommendations for the early diagnosis of COPD: the AIMAR view
por: Celli, Bartolome R
Publicado: (2015)

Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS
por: Putcha, Nirupama, et al.
Publicado: (2018)

Altered Gene Expression in Blood and Sputum in COPD Frequent Exacerbators in the ECLIPSE Cohort
por: Singh, Dave, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_b47n2krn5h836421o48u7eg8o5